⚠
Strictly for Research Purposes Only
This product is not for diagnostic, or therapeutic use. It is not approved by the FDA or MHRA. Purchase is restricted to qualified researchers and institutions. Misuse may result in account termination and legal action.
Purity
99.0%+
Form
Lyophilized Powder
Grade
Research Grade
Storage
2–8°C / -20°C
🔬 Technical Specifications
Molecular Formula
C221H366N72O67S
Molecular Weight
5135.9 g/mol (free base)
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Gln-Ser-Asn-Ala
Purity
99.0%+
Appearance
White to off-white lyophilized powder
Shelf Life
24 months from manufacturing date
Storage
2–8°C (refrigerated) or -20°C (frozen) for long-term storage
Solubility
Soluble in sterile water or bacteriostatic water
Shipping & Handling
✓ Shipped in temperature-controlled packaging
✓ Same-day dispatch for orders before 2PM
✓ Discrete, plain packaging
🧪 Scientific Background
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate the pituitary gland to release growth hormone. It has been modified with an N-terminal hexenoyl group to enhance its stability and resistance to enzymatic degradation.
Mechanism of Action: Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the release of growth hormone. This promotes the production of insulin-like growth factor-1 (IGF-1), which plays a key role in regulating metabolism, reducing visceral fat, and supporting tissue repair.
Key References
• Falutz J, et al. “Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients with Lipodystrophy.” New England Journal of Medicine, 2010.
• Guaraldi G, et al. “Tesamorelin for the Treatment of HIV-Associated Lipodystrophy.” Current Opinion in HIV and AIDS, 2011.
Reviews
There are no reviews yet.